HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Aurolife OTC Fexofenadine, Tween Brands Just Shine Cosmetics Among Recalls

Executive Summary

Consumer health and cosmetic product recalls added to FDA database on 18 and 25 September also include lidocaine topicals Ridge Properties provides for use in OTC products marketed as pre-tattoo prep or for pain or itch relief after the products were found to be contaminated and above specification for lidocaine assay.

You may also be interested in...

Direct Seller's CBD Supplement Recall Mandated, More Ranitidine, Tween Cosmetic Recalls

FDA's latest recalls records update includes Basic Reset CBD supplements and another 4,300 units of Tween Brands cosmetics containing colors made from banned dye. Recalls resulting from testing of ranitidine drugs reported by Dr. Reddy's.

Sandoz Recalls Antacid In Another Generics Firestorm

The Novartis unit moved to recall all lots of ranitidine capsules in the US due to confirmed contamination with NDMA.

US Zantac Sales And Distribution Continue As Sanofi Tests For NDMA

Novartis, which licensed OTC Zantac for US marketing to Sanofi, stops distribution of the histamine-2 blocker ranitidine to presence of NDMA, a probable carcinogen. Decision doesn’t affect US sales of OTC Zantac in US, where FDA says NDMA found in ingredient is at low levels.


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts